Johnson & Johnson temporarily halts Covid-19 vaccine output: report
NYSE - LSE
| RBGPF | 0.69% | 74.94 | $ | |
| CMSD | 0.9% | 23.27 | $ | |
| GSK | -4.9% | 37.15 | $ | |
| SCS | 0% | 10.33 | $ | |
| AZN | -4.79% | 73.09 | $ | |
| RIO | 0.47% | 59.77 | $ | |
| CMSC | 1.09% | 22.85 | $ | |
| SCU | 0% | 12.72 | $ | |
| RELX | 0.21% | 51.89 | $ | |
| BCC | -1.29% | 83.81 | $ | |
| BCE | -0.86% | 23.33 | $ | |
| NGG | 0.28% | 70.39 | $ | |
| RYCEF | 7.62% | 14.18 | $ | |
| JRI | 0.15% | 13.13 | $ | |
| BP | -0.31% | 32.15 | $ | |
| BTI | 0.97% | 53.68 | $ | |
| VOD | -2.31% | 10.81 | $ |
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.
The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.
J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.
The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.
J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.
"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.
J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.
But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.
Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.
C.Ricci--GdR
